rabbit ficolin (Bioss)
Bioss is a verified supplier 
Bioss manufactures this product 
92
Structured Review
Bioss
rabbit ficolin
Rabbit Ficolin, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+ficolin/pmc09679423-92-11-16?v=Bioss
Average 92 stars, based on 3 article reviews
Rabbit Ficolin, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+ficolin/pmc09679423-92-11-16?v=Bioss
Average 92 stars, based on 3 article reviews
rabbit ficolin - by Bioz Stars,
2026-08
92/100 stars
Images
1) Product Images from "Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer"
Article Title: Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer
Journal: Frontiers in Oncology
doi: 10.3389/fonc.2022.987481
Figure Legend Snippet: Expression levels of 17 genes based on GEPIA2 (Gene Expression Profiling Interactive Analysis web server). (A) ANGPTL6 . (B) CFP . (C) CLEC1B . (D) CLEC4G . (E) CLEC4M . (F) COLEC10 . (G) CRHBP . (H) CXCL12 . (I) DNASE1L3 . (J) FCN2 . (K) FCN3 . (L) GSTZ1 . (M) LCAT . (N) NAT2 . (O) OIT3 . (P) RSPO3 . (Q) VIPR1 . * p < 0.05. The y -axis represents the relative log2 expression value (TPM + 1).
Techniques Used: Expressing
Figure Legend Snippet: Survival analysis of 17 genes. (A) ANGPTL6 . (B) CFP . (C) CLEC1B . (D) CLEC4G . (E) CLEC4M . (F) COLEC10 . (G) CRHBP . (H) CXCL12 . (I) DNASE1L3 . (J) FCN2 . (K) FCN3 . (L) GSTZ1 . (M) LCAT . (N) NAT2 . (O) OIT3 . (P) RSPO3 . (Q) VIPR1 . (R) Constructed protein–protein interaction (PPI) network of the important differentially expressed genes (DEGs) using STRING. (S) Use of the Cytoscape plug-in MCODE to select the most important module from the PPI network.
Techniques Used: Construct
Figure Legend Snippet: Pan-tissue expression of FCN2 . (A) Pan-cancer expression of FCN2 in the Oncomine database. (B) Expression of FCN2 in normal tissues in the BioGPS database. (C) Pan-cancer expression of FCN2 in the UCSC (University of California, Santa Cruz) database. (D) Log2 transformation of the pan-cancer expression value of FCN2 in the UCSC database. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns: not statistically significant.
Techniques Used: Expressing, Transformation Assay
Figure Legend Snippet: Transcription levels of FCN2 in liver cancer and normal tissues. (A–C) Expression differences of the FCN2 gene between liver cancer tissues and normal tissues in the Oncomine database. (D) FCN2 mRNA expression in liver cancer tissue and normal tissue based on the GEPIA2 database (TCGA tumors vs . TCGA normal). (E, F) FCN2 protein expression in hepatocellular carcinoma in the UALCAN database. (G) Part of the results of the immunohistochemistry experiments. (H) Average optical density of liver cancer tissues and adjacent tissues from 30 liver cancer patients. TCGA , The Cancer Genome Atlas. * p < 0.05, *** p < 0.001.
Techniques Used: Expressing, Immunohistochemistry
Figure Legend Snippet: Different expression levels of FCN2 in liver hepatocellular carcinoma (LIHC) based on The Cancer Genome Atlas (TCGA) analyzed using R. (A) Pathologic stages. (B) Histological grade. (C) Fibrosis Ishak scale scores. (D) Race. (E) Normal tissue and liver cancer. (F) Adjacent hepatic tissue inflammation. (G) Age (H) . BMI. (I) Alpha-fetoprotein (AFP). (J) Vascular invasion. (K) Gender. * p < 0.05, ** p < 0.01, *** p < 0.001. ns: not statistically significant.
Techniques Used: Expressing
Figure Legend Snippet: Prognostic value of FCN2 in liver cancer. (A–D) Overall survival (OS) (A) , relapse-free survival (RFS) (B) , disease-specific survival (DSS) (C) , and patient-free survival/progression-free survival (PFS) (D) . (E) Nomogram predicting the 1-, 3-, and 5-year OS probability. (F) C-index of the prognostic model nomogram for predicting the 1-, 3-, and 5-year OS probability in hepatocellular carcinoma (HCC) patients. (G) Prediction of the 1-, 3-, and 5-year OS probability using nomogram calibration plots.
Techniques Used:
Figure Legend Snippet: Protein–protein interaction network analysis and enrichment analysis. (A, B) Gene network diagram of interaction with FCN2 created using the STRING database. (C–G) Diagrams of the analyses of the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathways.
Techniques Used:
Figure Legend Snippet: Correlation of FCN2 expression with immune characteristics. (A) Differential distribution of the immune cells in patients with high and low FCN2 expressions. (B–G) Correlation between the expression level of FCN2 and immune infiltration in hepatocellular carcinoma: (B) Neutrophils, (C) Eosinophils, (D) NK cells, (E) Tcm, (F) DC, (G) Th2 cells. * p < 0.05, ** p < 0.01, *** p < 0.001. ns, no significance.
Techniques Used: Expressing
Figure Legend Snippet: Correlation analysis between FCN2 and the biomarkers of immune cells in hepatocellular carcinoma (HCC) determined using the GEPIA database (Spearman’s correlation coefficient).
Techniques Used:
Figure Legend Snippet: Immunomodulators, chemokines, and receptors associated with FCN2 . (A) Distribution of the FCN2 immunological scores in tumor and normal tissues.The ordinate reflects the distribution of the immunological scores in distinct groups, whereas the abscissa indicates the immune cell types. The Wilcoxon test was used to compare statistical differences between the two groups, and the Kruskal–Wallis test was used to determine the significance of the differences between three groups. ( a ) Heatmap of the immune cell scores. Different hues represent the varied expression distributions in different samples. Asterisks indicate significance levels at * p < 0.05, ** p < 0.01, and *** p < 0.001. ( b ) Percentages of tumor-infiltrating immune cells in each sample. Different colors depict the different types of immunological cells. The abscissa denotes the sample, whereas the ordinate denotes the percentage of immune cells in a single sample. (H) Immunomodulators, chemokines, and receptors associated with FCN2 in liver hepatocellular carcinoma (LIHC). (B) CCL14. (C) CCL16. (D) CCL23. (E) TNFSF4. (F) CD276. (G) TNFRSF4. (H) KDR. **** p < 0.0001.
Techniques Used: Expressing
![Immunohistochemical comparison of FCN2 and the molecules with strong correlations [based on the Human Protein Atlas (HPA)].](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9423/pmc09679423/pmc09679423__fonc-12-987481-g011.jpg "Immunohistochemical comparison of FCN2 and the molecules with strong correlations [based on ...")
Figure Legend Snippet: Immunohistochemical comparison of FCN2 and the molecules with strong correlations [based on the Human Protein Atlas (HPA)].
Techniques Used: Immunohistochemical staining